Skip to content

Revance Therapeutics, Inc.

CIK 0001479290

← back to feed
Revenue (TTM)
$231.32M
+76.5% YoY Q3 Oct 2024
Net Income (TTM)
−$269.92M
+9.1% YoY Q3 Oct 2024
EPS Diluted (TTM)
−$2.94
+21.8% YoY Q3 Oct 2024
Gross Margin
—
Q3 Oct 2024
Operating Margin
-65.3%
Q3 Oct 2024
Net Margin
-116.7%
Q3 Oct 2024
Free Cash Flow (TTM)
−$279.54M
Q3 Oct 2024
Cash
$58.59M
Q3 Oct 2024
Total Debt
$431.19M
Q3 Oct 2024
Shares Outstanding
104.9M sh
Q3 Oct 2024

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings